Lupus News and Research RSS Feed - Lupus News and Research

Systemic lupus erythematosus (SLE), also called lupus, is an autoimmune disorder characterized by the immune system attacking the body's own tissues and organs, leading to inflammation and damage. The severity of the disease varies, from mild cases only involving the skin to severe cases affecting multiple organs, including the brain. Lupus sufferers experience flares, or intervals of active disease, and remissions in disease. The disease most predominantly occurs in women of childbearing age, but also affects children, adolescents, and men. While the cause of lupus is still unknown, various genetic, environmental, and infectious causes have been associated with its development. Current treatments for lupus vary depending on the extent of the disease, and may change over time. Some medications used to ease symptoms include nonsteroidal anti-inflammatory drugs, antimalarial drugs, corticosteroids, and immunosuppressive medications, though many of these drugs carry their own risks.
ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

Molecular Medicine, a peer-reviewed biomedical journal published by the Feinstein Institute Press, published the results of a new study reporting clinically significant pain reduction in type 2 diabetic patients. In an exploratory study conducted by Araim Pharmaceuticals, a biotech company developing novel treatments for chronic diseases, investigators also observed improvements in metabolic control in patients administered ARA 290. [More]
Study: Key protein may help prevent tumor growth, promote wound healing

Study: Key protein may help prevent tumor growth, promote wound healing

A key protein may represent a new way to use the immune system to speed healing and counter inflammatory, infectious and autoimmune diseases, according to study led by researchers at the Icahn School of Medicine at Mount Sinai and published in the December issue of Cell Reports. [More]
Phenotyping human diseases in mice: an interview with Professor Carola Vinuesa

Phenotyping human diseases in mice: an interview with Professor Carola Vinuesa

One of the main obstacles to finding effective therapies for human diseases has been our limited understanding of disease pathogenesis: we lack detailed knowledge of the cellular and molecular mechanisms that lead to the development of disease. [More]
BIDMC's George Tsokos receives two prestigious awards at 2014 ACR Annual Scientific Meeting

BIDMC's George Tsokos receives two prestigious awards at 2014 ACR Annual Scientific Meeting

George Tsokos, MD, Chief of Rheumatology at Beth Israel Deaconess Medical Center and a national leader in the field of lupus research was honored by both the Lupus Foundation of America and the American College of Rheumatology with two prestigious awards presented during the 2014 ACR Annual Scientific Meeting recently held in Boston. [More]
Scientists identify how ADAR1 gene mutation can lead to diseases

Scientists identify how ADAR1 gene mutation can lead to diseases

Scientists have discovered how a gene mutation can lead to diseases that occur when the immune system attacks the body by mistake. [More]

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Anthera Pharmaceuticals, Inc., today announced financial results and operational update for the third quarter ended September 30, 2014. [More]
SQI Diagnostics gets FDA clearance to market Celiac Panel in the US

SQI Diagnostics gets FDA clearance to market Celiac Panel in the US

SQI Diagnostics Inc. today announced that it has received notice that the United States Food and Drug Administration has cleared the Company to market its proprietary Celiac Panel in the United States (US). [More]
Health benefits of modified formulation of curcumin supplements

Health benefits of modified formulation of curcumin supplements

The health benefits of over-the-counter curcumin supplements might not get past your gut, but new research shows that a modified formulation of the spice releases its anti-inflammatory goodness throughout the body. [More]
Melbourne researchers reveal key steps involved in programmed cell death

Melbourne researchers reveal key steps involved in programmed cell death

Melbourne researchers have uncovered key steps involved in programmed cell death, offering new targets for the treatment of diseases including lupus, cancers and neurodegenerative diseases. [More]
Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

Though therapies are in their nascent phase, sales of stem cell technologies are expected to show an annual increase of 16.2% over the 2010-2020 period, reaching an expected market value of nearly $1 billion, according to Kalorama Information's report, Stem Cell Therapeutics Markets. [More]
Lactobacillus-containing probiotics can improve lupus symptoms

Lactobacillus-containing probiotics can improve lupus symptoms

Lactobacillus species, commonly seen in yogurt cultures, correlate, in the guts of mouse models, with mitigation of lupus symptoms, while Lachnospiraceae, a type of Clostridia, correlate with worsening, according to research published ahead of print in Applied and Environmental Microbiology. [More]
Scientists identify two microRNA molecules that control chronic inflammation

Scientists identify two microRNA molecules that control chronic inflammation

University of Utah scientists have identified two microRNA molecules that control chronic inflammation, a discovery that one day may help researchers prevent certain fatal or debilitating conditions before they start. [More]
Researchers identify two microRNA molecules that control chronic inflammation

Researchers identify two microRNA molecules that control chronic inflammation

University of Utah scientists have identified two microRNA molecules that control chronic inflammation, a discovery that one day may help researchers prevent certain fatal or debilitating conditions before they start. [More]
OMRF scientist selected to receive EMD Serono's Grant for Multiple Sclerosis Innovation

OMRF scientist selected to receive EMD Serono's Grant for Multiple Sclerosis Innovation

An Oklahoma Medical Research Foundation scientist has been selected to receive one of only five Grants for Multiple Sclerosis Innovation awarded this year by the pharmaceutical company EMD Serono. [More]

Eli Lilly to discontinue development of tabalumab due to insufficient efficacy in Phase 3 Lupus trials

Eli Lilly and Company announced today it will discontinue development of tabalumab­ -- being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) -- due to insufficient efficacy in two pivotal Phase 3 trials. The decision was not based on safety concerns. ­­­­ [More]
Mission Pharmacal adds Ovace Plus Lotion to its range of product offerings

Mission Pharmacal adds Ovace Plus Lotion to its range of product offerings

Itch. Scratch. Repeat. Irritating skin conditions, such as seborrheic dermatitis (SD), can create a distracting, uncomfortable vicious circle for those affected. [More]
New findings could pave way for treating autoimmune diseases

New findings could pave way for treating autoimmune diseases

Scientists from A*STAR's Bioprocessing Technology Institute (BTI) have established a clearer relationship between two cells which serve our body's natural defence mechanisms against diseases and infections. [More]
NIH awards grants to 11 research groups to establish AMP RA/Lupus Network

NIH awards grants to 11 research groups to establish AMP RA/Lupus Network

The National Institutes of Health has awarded grants to 11 research groups across the United States to establish the Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus (AMP RA/Lupus) Network. [More]
New findings raise hope for novel class of drugs to treat lupus

New findings raise hope for novel class of drugs to treat lupus

New findings by a biomedical engineer and his team at the University of Houston raise hope for a new class of drugs to treat lupus that may not include the long list of adverse risks and side effects often associated with current treatments for this disease. [More]
AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. [More]